Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $176.96 in the prior trading day, Quest Diagnostics, Inc (NYSE: DGX) closed at $178.36%, Up $0.79%. In other words, the price has increased by $0.79 from its previous closing price. On the day, 0.65 million shares were traded. DGX stock price reached its highest trading level at $178.55 during the session, while it also had its lowest trading level at $177.09.
Ratios:
Our goal is to gain a better understanding of DGX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 62.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.29. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.09. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on April 02, 2025, initiated with a Buy rating and assigned the stock a target price of $195.
On March 04, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $185.
Leerink Partners Upgraded its Market Perform to Outperform on January 06, 2025, whereas the target price for the stock was revised from $169 to $174.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 06 ’25 when Plewman Patrick sold 5,535 shares for $175.00 per share. The transaction valued at 968,625 led to the insider holds 19,219 shares of the business.
Plewman Patrick bought 5,535 shares of DGX for $968,625 on Aug 06 ’25. On Jul 30 ’25, another insider, KUPPUSAMY KARTHIK, who serves as the SVP, Clinical Solutions of the company, sold 8,269 shares for $167.40 each. As a result, the insider received 1,384,231 and left with 10,660 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DGX now has a Market Capitalization of 19944751104 and an Enterprise Value of 26127828992. As of this moment, Quest’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.33, and their Forward P/E ratio for the next fiscal year is 17.23. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.90 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 2.483 whereas that against EBITDA is 12.696.
Stock Price History:
The Beta on a monthly basis for DGX is 0.53, which has changed by 0.18299401 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, DGX has reached a high of $182.38, while it has fallen to a 52-week low of $146.17. The 50-Day Moving Average of the stock is 2.48%, while the 200-Day Moving Average is calculated to be 7.09%.
Shares Statistics:
The stock has traded on average 1.10M shares per day over the past 3-months and 896200 shares per day over the last 10 days, according to various share statistics. A total of 112.00M shares are outstanding, with a floating share count of 111.27M. Insiders hold about 0.50% of the company’s shares, while institutions hold 94.52% stake in the company. Shares short for DGX as of 1752537600 were 4575330 with a Short Ratio of 4.14, compared to 1749772800 on 3639500. Therefore, it implies a Short% of Shares Outstanding of 4575330 and a Short% of Float of 4.67.
Dividends & Splits
In the trailing 12 months, DGX’s forward annual dividend rate was 3.1, compared to 3.10 this year. Against a Trailing Annual Dividend Yield of 0.017518083The stock’s 5-year Average Dividend Yield is 1.87. The current Payout Ratio is 39.15% for DGX, which recently paid a dividend on 2025-07-07 with an ex-dividend date of 2025-07-07. Stock splits for the company last occurred on 2005-06-21 when the company split stock in a 2:1 ratio.
Earnings Estimates
The firm’s stock currently is rated by 14.0 analysts. The consensus estimate for the next quarter is $2.42, with high estimates of $2.5 and low estimates of $2.35.
Analysts are recommending an EPS of between $9.81 and $9.69 for the fiscal current year, implying an average EPS of $9.75. EPS for the following year is $10.38, with 17.0 analysts recommending between $10.82 and $9.8.
Revenue Estimates
12 analysts predict $2.73B in revenue for the current quarter. It ranges from a high estimate of $2.77B to a low estimate of $2.71B. As of the current estimate, Quest Diagnostics, Inc’s year-ago sales were $2.49BFor the next quarter, 12 analysts are estimating revenue of $2.72B. There is a high estimate of $2.74B for the next quarter, whereas the lowest estimate is $2.69B.
A total of 16 analysts have provided revenue estimates for DGX’s current fiscal year. The highest revenue estimate was $10.93B, while the lowest revenue estimate was $10.8B, resulting in an average revenue estimate of $10.86B. In the same quarter a year ago, actual revenue was $9.87BBased on 16 analysts’ estimates, the company’s revenue will be $11.25B in the next fiscal year. The high estimate is $11.38B and the low estimate is $11.12B.
